Vascepa is a prescription medication used to reduce triglyceride levels in adults. It contains the active ingredient icosapent ethyl and is manufactured by Amarin Corporation. According to Drug Patent Watch [1], the patent for Vascepa expired in 2020, which means that other pharmaceutical companies can now produce a generic version of the drug.

However, it is important to note that just because a generic version of Vascepa is available, it does not necessarily mean that it is interchangeable with the brand-name drug. The generic version must meet the same standards for safety, effectiveness, and quality as the brand-name drug, but there may be slight differences in the inactive ingredients used in the formulation.

Additionally, it is important to consider your insurance coverage when switching from a brand-name drug to a generic version. According to Formulary Watch [2], Prime Therapeutics has removed Vascepa from its Medicare formularies, which means that it may not be covered by certain insurance plans. However, this does not necessarily mean that the generic version will not be covered.

It is also worth noting that Amarin Corporation recently lost a patent appeal for Vascepa [3]. This means that other pharmaceutical companies may be able to produce a generic version of the drug sooner than expected.

In conclusion, while a generic version of Vascepa is now available, it is important to speak with your healthcare provider and insurance company before switching from the brand-name drug to the generic version. They can provide guidance on whether the generic version is appropriate for your specific needs and whether it will be covered by your insurance plan.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.formularywatch.com/view/prime-therapeutics-two-drugs-from-medicare-formularies
[3] https://www.fiercepharma.com/marketing/it-s-confirmed-amarin-loses-patent-appeal-protecting-blockbuster-hopeful-vascepa-from